Cannabis Info – Page 59 – TokeTheMost.com

French Excellence at the Heart of a High-Capacity EU-GMP Site

PGP Farmer closes a €3m funding round to become a leading player in EU-GMP medical cannabis production in Europe

French biotech company PGP Farmer unveils the closing of a €3 million funding round with private investors. Driven by the upcoming nationwide rollout of medical cannabis in France, this funding marks a key milestone in the company’s ambition to become a strategic pillar in the production and supply of medical cannabis in Europe.

A new milestone in France, with Europe in sight

Led by Brahim Sebart, Co-founder and CEO, this round enables PGP Farmer to reach a new milestone in the implementation of its large-scale pharmaceutical project. The project aims to position the company as a strategic producer of raw materials and medical cannabis extracts in Europe.

While European demand is growing by more than 20% per year, the supply remains largely dependent on imports: approximately 75% of flowers in the European Union currently come from sources outside Europe, particularly Canada.

To address this strategic imbalance, PGP Farmer’s production site is designed to meet the massive growth in demand across Europe. It specifically aims to meet the needs of Germany, the leading European market, which imported nearly 200 tons in 2025. Thanks to its immediate proximity, the French company benefits from a strategic geographical position for export.

“This funding is the driving force behind our ambition: to make France a leading player in medical cannabis in Europe. While the European market remains largely dependent on imports today, we have decided to build a model of excellence focused on export,” emphasises Brahim Sebart.

Scale and Innovation: 9-hectare model

PGP Farmer’s goal is to deploy a cutting-edge integrated model on a 9-hectare site, combining high-tech greenhouse cultivation and a pharmaceutical processing laboratory.

With a building permit already granted, this model guarantees a 100% controlled value chain and a production capacity of up to 30 tons in the long term, once the facility is fully operational. This funding aims to enable PGP Farmer to pursue three strategic ambitions:

Build a European pharmaceutical leader: Establish a production facility that strictly complies with the most demanding agricultural (GACP) and pharmaceutical (EU-GMP) standards.
Meeting French and international demand: Supplying the most demanding markets by guaranteeing consistent volumes and quality to secure the European value chain and ensure continuity of supply.
Driving innovation to meet patient needs: Deploying a high-capacity model to guarantee full traceability for a European patient base expected to exceed 1.5 million in 2026.

A strategic funding round at a pivotal moment

The funding comes ahead of France’s nationwide rollout of medical cannabis. This follows a pilot programme that enabled more than 3,000 French patients to benefit from medical cannabis for serious conditions, including:

Neuropathic pain
Severe epilepsy
Multiple sclerosis
Oncology and palliative care

As an active member of UIVEC (the industry’s professional trade association), PGP Farmer worked alongside leading international players on the joint assessment dossier submitted to the French National Authority for Health (HAS).

“The French market is entering a new era. By combining our institutional approach with a state-of-the-art EU-GMP site, we are giving ourselves the means to become a leading EU-GMP medical cannabis producer and to make France the focal point for European medical cannabis,” says Brahim Sebart.

The company will be participating in the Cannabis Europa Paris event on February 19, 2026, where Brahim Sebart will be a panelist showcasing an innovative and outstanding French industry.